论文部分内容阅读
目的:探讨美沙拉秦对缓解期溃疡性结肠炎(UC)患者血清炎性因子水平的影响。方法:收集2013年5月至2016年5月于我院治疗的缓解期UC患者153例,随机分为观察组75例及对照组78例。对照组患者给予常规治疗,观察组在对照组的基础上加用美沙拉秦治疗。观察比较两组治疗前后的血清白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、白细胞介素-17(IL-17)、肿瘤坏死因子-α(TNF-α)水平、疾病活动指数(DAI)评分、临床疗效、病情复发和不良反应的发生情况。结果:治疗后,观察组治疗总有效率为96.0%,明显高于对照组的62.8%(P<0.05);观察组的血清IL-6、IL-8、IL-17及TNF-α水平均较治疗前明显降低,且显著低于对照组(P<0.05);两组的DAI评分均有明显改善,但观察组的改善幅度明显大于对照组(P<0.05);观察组患者的复发率(2.6%)显著低于对照组(21.8%)(P<0.05),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:美沙拉秦治疗缓解期溃疡性结肠炎的临床疗效显著,可显著抑制患者的炎症反应,同时可改善患者的临床症状,降低复发率,且安全性高。
Objective: To investigate the effect of mesalamine on the levels of serum inflammatory cytokines in patients with remission of ulcerative colitis (UC). Methods: A total of 153 UC patients who were treated in our hospital from May 2013 to May 2016 were randomly divided into observation group (75 cases) and control group (78 cases). Patients in the control group were given routine treatment. The observation group was treated with mesalazine on the basis of the control group. The levels of serum interleukin-6, interleukin-8, interleukin-17, tumor necrosis factor-α (TNF-α ) Level, disease activity index (DAI) score, clinical efficacy, relapse and adverse reactions. Results: After treatment, the total effective rate in the observation group was 96.0%, which was significantly higher than that in the control group (62.8%, P <0.05). The levels of IL-6, IL-8, IL-17 and TNF- (P <0.05). DAI scores of both groups were significantly improved, but the improvement rate of the observation group was significantly greater than that of the control group (P <0.05). The recurrence rate of the observation group was significantly higher than that of the control group (2.6%) was significantly lower than that of the control group (21.8%) (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Mesalazine treatment of remission in patients with ulcerative colitis significantly curative effect, can significantly inhibit the patient’s inflammatory response, and can improve the patient’s clinical symptoms, reduce the recurrence rate, and high safety.